The invention discloses a BRS-3
antagonist and application thereof in treating and / or preventing
myocardial cell injury related diseases, and belongs to the field of biological
medicine. It is found for the first time that licoflavone A and saikoside B2 can antagonize
calcium ion (Ca < 2 + >) influx induced by a BRS-3 specific
agonist MK5046 in a
dose-dependent mode, and it is revealed that licoflavone A and saikoside B2 can serve as BRS-3
receptor antagonists to play a role. According to the application, an
oxidative stress environment is simulated through
hydrogen peroxide to explore the influence of licoflavone A of a BRS-3
receptor on
myocardial cell activity, it is found for the first time that licoflavone A and bantag-1 can relieve
myocardial cell injury caused by H2O2 by antagonizing BRS-3, it is revealed that the BRS-3
receptor possibly becomes a treatment target of myocardial injury caused by
oxidative stress, and the application has a wide application prospect. The
antagonist can be used for preparing medicines or health-care foods for treating or preventing myocardial
cell injury related diseases.